Skip to main content
Erschienen in: Familial Cancer 1/2007

01.03.2007 | Original paper

Familial colorectal cancer referral to regional genetics department—a single centre experience

verfasst von: Tony Mak, Douglas Speake, Fiona Lalloo, James Hill, D. G. R. Evans

Erschienen in: Familial Cancer | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Evaluation of familial colorectal cancer referral can assist in the planning of future cancer surveillance. The aim of the study is to assess colorectal cancer referral pattern to our regional genetics service. Hospital computer records and/or department referral books were used to identify cases referred to the regional genetic service during a 10-year period (1992–2001 inclusive). All files were reviewed along with associated demographic data, risk assessments, referral details, results from mutation testing and screening recommendations. In terms of result, a total of 1,100 family files were reviewed (Familial Adenomatous Polyposis families were in a separate register). The number of referrals showed a 10-fold increase over the 10 years. 171 (15.6%) of families met the Amsterdam criteria II were classified as high-risk, 589 (53.5%) families were classified as moderate-risk and 337 (31.0%) as average or low risk. 22.9% families were referred with inaccurate cancer history. Sixty-one families have been identified with mismatch repair mutations. 56.8% of referred individuals were recommended to have regular colonoscopy ranging from 18 monthly to 5 yearly depending on their risks. In conclusion, there has been a 10-fold increase in individuals with suspected hereditary bowel cancer referred to the North West Regional Genetics Service in the last ten years. Genetic assessment may reduce the number of low-risk individuals and those who were found not to be mutation carriers from having unnecessary colonoscopic screening. Thus genetic risk assessment should precede the initiation of regular endoscopic screening.
Literatur
1.
Zurück zum Zitat Parkin DM, Pisani P, Ferlay J (1993) Estimates if the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606PubMed Parkin DM, Pisani P, Ferlay J (1993) Estimates if the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594–606PubMed
2.
Zurück zum Zitat The Cancer Research UK Website. http://www.cancerresearch.org.uk/aboutcancer/statistics/cancerstatreport/ [1 December 2003] The Cancer Research UK Website. http://​www.​cancerresearch.​org.​uk/​aboutcancer/​statistics/​cancerstatreport​/​ [1 December 2003]
3.
Zurück zum Zitat Hayne D, Brown RSD, McCormack M et al (2001) Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol 13:448–452 Hayne D, Brown RSD, McCormack M et al (2001) Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol 13:448–452
4.
Zurück zum Zitat Lynch HT, Smyrk T (1998) An update on Lynch syndrome. Curr Opin Oncol 10(4):349–356PubMed Lynch HT, Smyrk T (1998) An update on Lynch syndrome. Curr Opin Oncol 10(4):349–356PubMed
5.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116(6):1453–1456PubMedCrossRef
6.
Zurück zum Zitat Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef Jarvinen HJ, Aarnio M, Mustonen H et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5):829–834PubMedCrossRef
7.
Zurück zum Zitat de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45(12):1588–1594 de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al (2002) Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 45(12):1588–1594
8.
Zurück zum Zitat Vasen HFA, Watson P, Mecklin J-P, Lynch HT, ICG-HNPCC (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456 Vasen HFA, Watson P, Mecklin J-P, Lynch HT, ICG-HNPCC (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116:1453–1456
9.
Zurück zum Zitat Hodgson S, Maher ER (1999) A practical guide to human cancer genetics, 1st edn. Cambridge University Press, Cambridge Hodgson S, Maher ER (1999) A practical guide to human cancer genetics, 1st edn. Cambridge University Press, Cambridge
10.
Zurück zum Zitat Hildreth NG, Kelsey JL, LiVolsi VA et al (1981) An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114(3):398–405PubMed Hildreth NG, Kelsey JL, LiVolsi VA et al (1981) An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 114(3):398–405PubMed
11.
Zurück zum Zitat Rodriguez-Bigas MA, Boland CR, Hamiliton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRef Rodriguez-Bigas MA, Boland CR, Hamiliton SR et al (1997) A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 89:1758–1762PubMedCrossRef
12.
Zurück zum Zitat Liu B, Parsons R, Papadopoulos N et al (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2(2):169–174PubMedCrossRef Liu B, Parsons R, Papadopoulos N et al (1996) Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 2(2):169–174PubMedCrossRef
13.
Zurück zum Zitat Taylor CF, Charlton RS, Burn J et al (2003) Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 22(6):428–433PubMedCrossRef Taylor CF, Charlton RS, Burn J et al (2003) Genomic deletions in MSH2 or MLH1 are a frequent cause of hereditary non-polyposis colorectal cancer: identification of novel and recurrent deletions by MLPA. Hum Mutat 22(6):428–433PubMedCrossRef
14.
Zurück zum Zitat Nakagawa H, Hampel H, de la Chapelle A (2003) Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 22(3):258PubMedCrossRef Nakagawa H, Hampel H, de la Chapelle A (2003) Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 22(3):258PubMedCrossRef
15.
Zurück zum Zitat Wonderling D, Hopwood P, Cull A et al (2001) A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. Br J Cancer 85(2):166–170PubMedCrossRef Wonderling D, Hopwood P, Cull A et al (2001) A descriptive study of UK cancer genetics services: an emerging clinical response to the new genetics. Br J Cancer 85(2):166–170PubMedCrossRef
16.
Zurück zum Zitat Moynihan C (1998) Theories in health care and research: theories of masculinity. BMJ 317(7165):1072–1075PubMed Moynihan C (1998) Theories in health care and research: theories of masculinity. BMJ 317(7165):1072–1075PubMed
17.
Zurück zum Zitat Mak T, Lalloo F, Evans DG et al (2004) Molecular stool screening for colorectal cancer. Br J Surg 91(7):790–800PubMedCrossRef Mak T, Lalloo F, Evans DG et al (2004) Molecular stool screening for colorectal cancer. Br J Surg 91(7):790–800PubMedCrossRef
18.
Zurück zum Zitat Ahlquist DA, Skoletsky JE, Boynton KA et al (2000) Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119(5):1219–1227PubMedCrossRef Ahlquist DA, Skoletsky JE, Boynton KA et al (2000) Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119(5):1219–1227PubMedCrossRef
19.
Zurück zum Zitat Glanz K, Grove J, Lerman C et al (1999) Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiol Biomarkers Prev 8(4 Pt 2):329–336PubMed Glanz K, Grove J, Lerman C et al (1999) Correlates of intentions to obtain genetic counseling and colorectal cancer gene testing among at-risk relatives from three ethnic groups. Cancer Epidemiol Biomarkers Prev 8(4 Pt 2):329–336PubMed
20.
Zurück zum Zitat Mitchell RJ, Brewster D, Campbell H et al (2004) Accuracy of reporting of family history of colorectal cancer. Gut 53(2):291–295PubMedCrossRef Mitchell RJ, Brewster D, Campbell H et al (2004) Accuracy of reporting of family history of colorectal cancer. Gut 53(2):291–295PubMedCrossRef
21.
Zurück zum Zitat Katballe N, Juul S, Christensen M et al (2001) Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br J Surg 88(9):1228–1233PubMedCrossRef Katballe N, Juul S, Christensen M et al (2001) Patient accuracy of reporting on hereditary non-polyposis colorectal cancer-related malignancy in family members. Br J Surg 88(9):1228–1233PubMedCrossRef
22.
Zurück zum Zitat Church J, McGannon E (2000) Family history of colorectal cancer: how often and how accurately is it recorded? Dis Colon Rectum 43(11):1540–1544PubMedCrossRef Church J, McGannon E (2000) Family history of colorectal cancer: how often and how accurately is it recorded? Dis Colon Rectum 43(11):1540–1544PubMedCrossRef
23.
Zurück zum Zitat Aitken J, Bain C, Ward M et al (1995) How accurate is self-reported family history of colorectal cancer? Am J Epidemiol 141(9):863–871PubMed Aitken J, Bain C, Ward M et al (1995) How accurate is self-reported family history of colorectal cancer? Am J Epidemiol 141(9):863–871PubMed
24.
Zurück zum Zitat Syngal S, Fox EA, Eng C et al (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641–645PubMedCrossRef Syngal S, Fox EA, Eng C et al (2000) Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 37:641–645PubMedCrossRef
Metadaten
Titel
Familial colorectal cancer referral to regional genetics department—a single centre experience
verfasst von
Tony Mak
Douglas Speake
Fiona Lalloo
James Hill
D. G. R. Evans
Publikationsdatum
01.03.2007
Verlag
Kluwer Academic Publishers
Erschienen in
Familial Cancer / Ausgabe 1/2007
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-006-9108-6

Weitere Artikel der Ausgabe 1/2007

Familial Cancer 1/2007 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.